Chalcone Glycoside Crystal Forms for Vascular Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development for vascular diseases, particularly those involving ischemia-reperfusion injury and thrombosis, lacks effective neuroprotective agents that can inhibit inflammation and oxidative stress while enhancing thrombolysis, and the study of polymorphic forms of chalcone glycosides is lacking in understanding their impact on stability and solubility.
Innovation Solution
Development of polymorphic forms of chalcone glycoside compounds, including crystal form A, B, amorphous form, and mixed crystals, through methods such as salification, recrystallization, and solvent diffusion, which exhibit significant antiplatelet aggregation and free radical scavenging properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chalcone glycoside compounds are developed as neuroprotective agents for vascular diseases, then the efficacy and safety of thrombolysis can be improved, but the complexity of drug development and clinical translation increases
Solution Approach 1:
The patent explores different polymorphic forms (crystal forms A and B, amorphous form) of chalcone glycoside compounds to optimize their physical and chemical properties. By changing the physical state and crystal structure parameters, the study aims to improve stability, solubility, and bioavailability while maintaining neuroprotective and antiplatelet effects, thereby enhancing thrombolysis efficacy without increasing development complexity
Solution Approach 2:
The patent creates mixed crystal forms combining different polymorphic forms of chalcone glycoside compounds. This composite approach allows the integration of advantageous properties from different forms (e.g., stability from crystal form A, solubility from crystal form B) to achieve superior overall performance as neuroprotective agents
2Stability of the object's composition
If polymorphic forms of chalcone glycoside compounds are studied to improve stability and solubility, then pharmacokinetic properties can be optimized, but the research and development time increases
Solution Approach 1:
The patent conducts preliminary characterization of different polymorphic forms through X-ray diffraction, NMR spectroscopy, and thermal analysis before clinical trials. By pre-determining stability, solubility, and pharmacokinetic properties of various forms, the study can select the optimal form for development, reducing time-consuming trial-and-error during clinical phases
Solution Approach 2:
The study systematically evaluates how changes in physical parameters (crystal structure, polymorphic form) affect pharmacokinetic properties. By establishing structure-activity relationships and predicting bioavailability based on physical form, the research can accelerate drug development while ensuring optimized stability and solubility
3Reliability
If chalcone glycoside compounds are used to inhibit platelet aggregation and oxidative stress, then vascular disease treatment can be enhanced, but the complexity of pharmacological testing and validation increases
Solution Approach 1:
The patent demonstrates that chalcone glycoside compounds exhibit multiple pharmacological activities simultaneously: neuroprotection, antiplatelet aggregation, antioxidant effects, and inhibition of oxidative stress. This multi-functionality allows a single compound to address multiple pathophysiological mechanisms of vascular diseases, reducing the need for multiple separate drug development programs and simplifying validation requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel chalcone glycoside compounds demonstrate enhanced stability and pharmacological effects, effectively inhibiting platelet aggregation and reducing reperfusion injury, offering a promising therapeutic approach for vascular diseases like stroke and coronary syndrome.
Implementation Method 1
Chalcone or its derivatives can scavenge a large amount of free radicals generated during ischemia-reperfusion injury and inflammatory response
Implementation Method 2
chalcone is an antagonist of platelet-activating factors (PAF), which can inhibit platelet aggregation and inflammatory response induced by PAF
Implementation Method 3
The chalcone glycoside compound is obtained by reacting an intermediate free acid of the chalcone glycoside compound with an alkaline compound of M
Data Source
AI summary
The present invention discloses a polymorphic form of a chalcone glycoside compound, and a preparation method and an application thereof in a medicament for treating a vascular disease. The chalcone glycoside compound has a structure of the general formula below or a hydrate thereof, where R1 and R2 are β-D-glucosyl or α-D-glucosyl; R3 is hydrogen or hydroxyl; and M is a metal ion, and n is 1-2. The chalcone glycoside compound described in the present invention can effectively inhibit platelet aggregation, has a protective effect against cell apoptosis, can significantly relieve ischemia/ischemia-reperfusion injury, increases a serum SOD content, and improves behavior disorders and tissue infarction focuses induced by ischemia-reperfusion. Moreover, this crystal form has a simple process, high purity and excellent stability, and has important significance for developing medicaments for treating vascular diseases with stronger therapeutic effects, lower toxicity and urgent clinical needs.